Obermatt

Bachem

SWX:BANB · CH1176493729
Life Sciences Tools & ServicesMedium

360

59
EV / EBIT41
Price / Owner Earnings90
Owner Earnings Yield1
Dividend Yield77
Price/Sales26
EV / Gross Profit3
Price/Book52
Return on Capital73
Cash Return on Capital29
Return on Equity66
EBIT Margin83
Gross Profitability17
Cash Conversion53
Accruals9
Owner Earnings Margin21
Sales growth87
Profit Growth69
Long-Term EPS Growth87
Reinvestment65
Price momentum78
Debt load78
Refinancing73
Debt Payback1
Liquidity100
Analyst ratings23
Opinion Changes50
Price Target Upside57
Market mood57
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Bachem clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySwitzerland
IndustryLife Sciences Tools & Services
SizeMedium
TypePublic Company
ExchangeSWX
Founded1971
Employees1,734
Websitebachem.com
ISINCH1176493729
Last UpdateApr 2, 2026
Themes
PharmacovigilanceBiomedical Engineering

Description

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies. The company specializes in providing contract development and manufacturing services (CDMO) to pharmace…

Analysis

Middle-of-the-road

Bachem Holding AG sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.

Valuation data is not available for this company.

Growth is solid; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
89
2023202420252026

All-time high

96

Mar 2026

All-time low

31

Nov 2025

Average rank

68

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
26
13
17
28
Price/Earnings
18
33
30
11
Price/Book
52
40
37
13
Dividend Yield
77
67
66
63
Value (overall)
51
70
34
35

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Bachem with its peers
Siegfried
SWX:SFZN
63
CountrySwitzerland
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Compugen
NAQ:CGEN
19
CountryIsrael
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Guerbet
PAR:GBT
4
CountryFrance
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
Evotec
GER:EVT
17
CountryGermany
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Formyco
GER:FYB
42
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
CRISPR Therapeutics
NMQ:CRSP
22
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →